Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility (generation of autologous clinical grade AdE1-LMP-specific CTL from the blood of EBV-positive lymphoma patients)
The investigational product for each participant will be assessed post production. The patient will have blood samples taken prior to and following each infusion, and then at 1, 3, 6 & 12 months following the final infusion.
No
Maher K Gandhi, MB CHB PhD
Principal Investigator
Queensland Institute of Medical Research
Australia: Department of Health and Ageing Therapeutic Goods Administration
QIMR P1167
NCT00779337
October 2008
May 2012
Name | Location |
---|